Total, Unbound, Renal, and Hepatic Clearances of Raltegravir and the Formation and Elimination Clearances of Raltegravir Glucuronide in Pregnant Women.
biliary excretion
elimination pathway
pharmacokinetics
uridine 5′ diphospho-glucuronosyltransferase
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
20
03
2023
accepted:
23
05
2023
medline:
23
10
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
ppublish
Résumé
This work aimed to evaluate the total, unbound, renal, and hepatic clearances of raltegravir (RAL) and the formation and elimination clearances of raltegravir glucuronide (RAL GLU) in pregnant women living with HIV. The participants received RAL 400 mg twice daily during the third trimester (n = 15) of gestation, delivery (n = 15), and the postpartum period (n = 8). Pharmacokinetic parameter values were calculated on the basis of plasma and urine data using noncompartmental methods. RAL clearances for the third trimester of gestation were as follows: total clearance: geometric mean, 63.63 L/h (95% CI, 47.5-85.25); renal clearance: geometric mean, 2.56 L/h (95% CI, 1.96-3.34); hepatic clearance: geometric mean, 60.52 L/h (95% CI, 44.65-82.04); and unbound clearance: geometric mean, 281.14 L/h (95% CI, 203.68-388.05). RAL GLU formation and elimination clearances for the third trimester of gestation were 7.57 L/h (95% CI, 4.94-11.6) and 8.71 L/h (95% CI, 6.71-11.32), respectively. No differences were observed in RAL GLU pharmacokinetic parameters between the third trimester of gestation and the postpartum period, except for higher formation (7.57 vs 4.03 L/h) and elimination (8.71 vs 4.92 L/h) clearances during the third trimester. The findings based on plasma and urine data are consistent with an increase in the hepatic uridine 5' diphospho-glucuronosyltransferase isoenzymes activities involved in RAL metabolism during pregnancy, and the formation of RAL GLU is a minor route of RAL elimination. Compared to the postpartum period, in the third trimester of gestation, the similar RAL plasma exposure in pregnant women reinforces the maintenance of an RAL regimen including a 400-mg oral dose twice daily during pregnancy.
Substances chimiques
Raltegravir Potassium
43Y000U234
Glucuronides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1053-1060Informations de copyright
© 2023, The American College of Clinical Pharmacology.
Références
WHO. Mother-to-child transmission of HIV. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/mother-to-child-transmission-of-hiv
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. HIV-1-Infected women for maternal health and interventions to recommendations for use of antiretroviral drugs in pregnant HIV-1-Infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States; 2020. https://clinicalinfo.hiv.gov/en/guidelines/perinatal/overview.
Arribas J, Marzolini C, Mallon P, et al. European AIDS Clinical Society (EACS) Guidelines. European AIDS Society (EACS); 2021.
Ministério da Saúde do Brasil. Protocolo clínico e diretrizes terapêuticas para prevenção da transmissão vertical de/ hiv, sífilis e hepatites virais. https://www.gov.br/aids/pt-br/centrais-de-conteudo/pcdts/2022/hiv-sifilis-e-hepatites-virais/pcdt_tv_internet_13-06-22-2.pdf
João EC, Morrison RL, Shapiro DE, et al. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial. Lancet HIV. 2020;7(5):e322-e331.
Amaral S, Brites C, Sprinz E. Integrase inhibitors use for HIV infection in pregnancy. Curr Infect Dis Rep. 2022;24:9-19.
Teixeira MLB, Fuller TL, Gouvêa MIFS, et al. Efficacy of three antiretroviral regimens initiated during pregnancy: clinical experience in Rio de Janeiro. Antimicrob Agents Chemother. 2020;64(12):e01068-20.
Cattaneo D, Gervasoni C, Meraviglia P, et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother. 2012;67:460-464.
Blonk MI, Colbers AP, Hidalgo-Tenorio C, et al. Pharmacokinetics of newly developed antiretroviral agents in HIV-infected pregnant women PANNA network; PANNA network. Raltegravir in HIV-1-infected pregnant women: pharmacokinetics, safety, and efficacy. Clin Infect Dis. 2015;61(5):809-816.
Watts DH, Stek A, Best BM, Wang J, et al. IMPAACT 1026s study team. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014;67(4):375-381.
Rizk ML, Hang Y, Luo WL, et al. Pharmacokinetics and pharmacodynamics of once daily versus twice-daily raltegravir in treatment-naïve HIV-infected patients. Antimicrob Agents Chemother. 2012;56;3101-3106.
Taburet AM, Sauvageon H, Grinsztejn B, et al. Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy. HIV/AIDS. 2015;61:1328-1335.
Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35(9):1657-1663.
Moreira FD, Tarozzo MM, Nardotto GH, Gonçalves JC, Schmidt S, de-Moraes NV. Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling. Eur J Pharm Sci. 2022;179:106309.
Liu SN, Lu JBL, Watson CJW, Lazarus P, Desta Z, Gufford BT. Mechanistic assessment of extrahepatic contributions to glucuronidation of integrase strand transfer inhibitors. Drug Metab Dispos. 2019;47(5):535-544.
Hoque MT, Kis O, Rosa MF, Bendayan R. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters. Antimicrob Agents Chemother. 2015;59(5):2572-2582.
Tsuchiya K, Hayashida T, Hamada A, Oka S, Gatanaga H. High peak level of plasma raltegravir concentration in patientswith ABCB1 and ABCG2 genetic variants. J Acquir Immune Defic Syndr. 2016;72(1):11-14.
Zheng Y, Hirt D, Delmas S, et al. Effect of pregnancy on unbound raltegravir concentrations in the ANRS 160 RalFe trial. Antimicrob Agents Chemother. 2020 21;64(10):e00759-20.
Moreira FL, Melli PPS, Marques MP, et al. P-glycoprotein and organic anion transporter polypeptide 1b/breast cancer resistance protein drug transporter activity in pregnant women living with HIV. J Clin Pharmacol. 2023;63(2):219-227.
Moreira FL, Marques MP, Duarte G, Lanchote VL. Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study. J Pharm Biomed Anal. 2020;177:112838.
Anker M, Corales RB. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. Exp Opin Investig Drugs. 2008;7(1):97-103.
Barau C, Furlan V, Yazdanpanah Y, et al. Characterization of binding of raltegravir to plasma proteins. Antimicrob Agents Chemother. 2013;57:5147-5150.
Neely M, Decosterd L, Fayet A, et al. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother. 2010;54(11):4619-4625.
Podany AT, Scarsi KK, Pham MM, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors: an updated review. Clin Pharmacokinet. 2020;59(9):1085-1107.
Carvalho S, Sheehan NL, Valois S, et al. Relationship between raltegravir trough plasma concentration and virologic response and the impact of therapeutic drug monitoring during pregnancy. Int J STD AIDS. 2022;18:9564624221144489.
Court MH, Zhang X, Ding X. Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adults and 3 fetal tissues. Xenobiotica. 2012;42(3):266-277.